

Applicants : Daniel J. Capon, Jeannette M. Whitcomb and
Neil T. Parkin
Serial No. : 09/126,559
Filed : July 30, 1998
Page 3

C1
INS
E1 wherein a test concentration of the HCV anti-viral drug is present at steps (a)-(c); at steps (b)-(c); or at step (c).

C2
4. (Amended) The method of claim 1 wherein the resistance test vector comprises genes encoding C, E1, E2, NS2, NS3, NS4, or NS5 proteins of HCV.--

C3
INS
E2 8. (Amended) The method of claim [5] 1, wherein the patient-derived segment comprises a functional viral sequence, said viral sequence having [comprises] an internal ribosome entry site (IRES) [IRES].-4

37. (Amended) A method for determining susceptibility for an HCV anti-viral drug comprising:

- C4*
INS
E2
- (a) introducing a resistance test vector comprising a patient-derived segment which comprises a hepatitis C virus (HCV) gene and a nonfunctional indicator gene into a host cell;
 - (b) culturing the host cell from (a);
 - (c) measuring expression of the indicator gene in a target host cell, wherein the expression of the indicator gene is dependent upon the patient-derived segment; and
 - (d) comparing the expression of the indicator gene from (c) with the expression of the indicator gene measured when steps (a)-(c) are carried out in the absence of the HCV anti-viral drug,
- wherein a test concentration of the HCV anti-viral drug is present at steps (a)-(c); at steps (b)-(c); or at step (c).-4